Successful Treatment of Inflammatory Dermatitis Associated With ALOXE3 Nonsyndromic Epidermal Differentiation Disorder Using Dupilumab
Abstract
ABSTRACT Dupilumab has emerged as a promising treatment for inflammatory dermatitis in some epidermal differentiation disorders (EDDs, formerly known as ichthyosis). We report a 5‐month‐old female with recurrent generalized skin peeling and erythematous plaques since birth that were refractory to multiple topical therapies; she was diagnosed with ALOXE3 ‐associated nonsyndromic epidermal differentiation disorder ( ALOXE3 ‐nEDD) by whole exome sequencing. Following initiation of dupilumab, she experienced near‐complete resolution of erythematous plaques within 9 months and improvement of pruritus, with sustained response over 2 years of treatment. This case highlights dupilumab as a potential treatment for inflammatory dermatitis associated with ALOXE3 ‐nEDD and similar EDDs.